BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Zecotek Medical Systems (ZMS.V) Files Patent Lawsuit Against Saint-Gobain Corporation and Philips


2/24/2012 10:06:20 AM

SINGAPORE, Feb. 23, 2012 /PRNewswire/ - Zecotek Photonics Inc. (TSX-V: ZMS) (Frankfurt: W1I), a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced that its subsidiary, Zecotek Imaging Systems Pte Ltd., has started legal action in United States Federal District Court in Los Angeles against defendants Saint-Gobain Corporation and Philips for infringement of Zecotek's U.S. Patent Number 7,132,060. Zecotek's patent covers the substances and chemical formulations used to grow lutetium fine silicate (LFS) scintillation crystals which are characterized by their combined high light yield and ultra-fast decay times and are typically used in medical scanning devices. The lawsuit alleges that Saint-Gobain's LYSO crystals infringe Zecotek's patent, and that Philips infringes by using those crystals in the PET scanners it sells.

"We believe that this patent is fundamental, and that damages are very substantial," said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek Photonics Inc. "Our management, engineers with its principal scientists Drs. Alexander I. Zagumennyi and Yuri D. Zavartsev, world leading crystal scientists and members of the Institute of the Russian Academy of Sciences, have invested significant resources in the development and commercialization of our LFS scintillation crystals, including our ultra-fast Ce:Ca:LSO/LYSO scintillators. We have spent many years of hard work to develop and secure this unique crystal technology. We are determined to vigorously enforce our intellectual property rights to recover damages afflicted on Zecotek and the lost value to our shareholders".

U.S. Patent # 7,132,060 covering Zecotek's LFS scintillation crystals was granted on November 6, 2006.

Zecotek is joined by its exclusive licensee for certain LFS crystals, Beijing Opto-Electronics Technology Co. Ltd., as co-plaintiff. Zecotek is being represented by Thomas Loop of the law firm of Graybeal Jackson LLP and Justin Nelson of Susman Godfrey LLP. Both firms are recognized leaders in patent law and intellectual property litigation matters.

About Zecotek
Zecotek Photonics Inc (TSX-V: ZMS; Frankfurt: W1I) is a photonics technology company developing high-performance crystals, photo detectors, medical lasers, optical imaging and 3D display technologies for commercial applications in the medical diagnostics and high-tech industry. Founded in 2003, the company has three distinct operating divisions: medical imaging, medical lasers and 3D display and labs located in Canada, Singapore and Russia. Zecotek commercializes its novel, patented and patent-pending bio-photonic technologies directly and through strategic alliances and joint ventures with multinational OEMs, distributors and other industry leaders. For more information, please visit www.zecotek.com.

This press release may contain forward-looking statements that are based on management's expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com.

SOURCE Zecotek Medical Systems Inc.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->